Abstract Number: 1754 • ACR Convergence 2022
Association of Cognitive Impairment and Symptomatic Lower Extremity Osteoarthritis by Level of Physical Activity: Preliminary Data from the Johnston County Health Study
Background/Purpose: While osteoarthritis (OA) is associated with an increased risk of dementia,1 the frequency of milder cognitive impairment is unknown. Mild to moderate cognitive impairment…Abstract Number: 0330 • ACR Convergence 2022
Assessing the Utility of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Impairment in Patients with SLE Using a Bayesian Item-Response Theory Model
Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric syndromes in patients with SLE, with a prevalence ranging from 20% to…Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…Abstract Number: 0363 • ACR Convergence 2022
Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus
Background/Purpose: Cognitive dysfunction (CD) is detectable in 40% of patients with systemic lupus erythematosus (SLE). Despite this high prevalence, there are limited treatment options for…Abstract Number: 2074 • ACR Convergence 2022
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
Background/Purpose: Cognitive dysfunction affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), particularly executive dysfunction (ED), with adverse effects on treatment adherence,…Abstract Number: 0517 • ACR Convergence 2022
Cortical Surface Area Correlates with Cognitive Efficiency and Disease Measures in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Cognitive difficulties are common in children with childhood-onset SLE (cSLE), but neuropsychiatric lupus (NPSLE) remains challenging to diagnose and treat. To increase understanding of…Abstract Number: 0665 • ACR Convergence 2022
Screening for Neurocognitive Demands in Childhood-onset Systemic Lupus Erythematosus Patients Using Pediatric Automated Neuropsychological Assessment Metrics and Association with Magnetic Resonance Imaging
Background/Purpose: Neuropsychiatric manifestations are frequently seen in patients with childhood-onset erythematosus (cSLE) and may include neurocognitive dysfunction. These symptoms are difficult to diagnose and classify…Abstract Number: 0793 • ACR Convergence 2022
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Background/Purpose: Up to 70% of the 236 million people who have been diagnosed with SARS-CoV-2 develop post-COVID symptoms. (1) This has been defined by the…Abstract Number: 1196 • ACR Convergence 2022
Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk of developing dementia. Systemic inflammation is implicated in the pathogenesis of cognitive decline. However, the association…Abstract Number: 0885 • ACR Convergence 2021
SLE Phenotypes Formed from Machine Learning and Their Associations with Cognitive Impairment
Background/Purpose: Cognitive impairment (CI) in SLE is a significant problem with limited treatment options. This is in part due to the uncertainty regarding the multifaceted…Abstract Number: 0887 • ACR Convergence 2021
Association of Mycophenolate and Azathioprine Use with Cognitive Function in SLE
Background/Purpose: Cognitive dysfunction (CD) is a common manifestation of systemic lupus erythematosus (SLE) which can have detrimental consequences for those affected. To date, no treatments…Abstract Number: 0889 • ACR Convergence 2021
Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a number of neuropsychiatric manifestations including cognitive impairment (CI). Previous meta-analyses have reported the prevalence of CI…Abstract Number: 0892 • ACR Convergence 2021
Screening for Cognitive Impairment with the Automated Neuropsychological Assessment Metrics in Patients with Systemic Lupus Erythematosus
Background/Purpose: The American College of Rheumatology Neuropsychological Battery (ACR-NB) is the standard screening test for cognitive impairment (CI) in systemic lupus erythematosus (SLE). While the…Abstract Number: 0895 • ACR Convergence 2021
Insight into Intraindividual Variability Across Neuropsychological Tests and Its Association with Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Background/Purpose: Dispersion is defined as the variability in an individual’s performance across multiple tasks at a single assessment visit. This measure has been studied in…Abstract Number: 1293 • ACR Convergence 2021
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
Background/Purpose: Systemic Lupus Erythematosus (SLE) has a high prevalence of cognitive impairment (CI) (38% (95% confidence interval: 33-43%)). Patient reported outcomes (PROs) capture patient perceptions…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »